Finerenone wins FDA clearance for type 1 diabetes–related CKD, lowering albuminuria in FINE-ONE and opening a long-awaited treatment path.
|Slideshows|June 4, 2018
Obesity Phenotypes: Origins and Implications
Author(s)Veronica Hackethal, MD
Three presentations at Digestive Disease Week 2018 shed light on proposed biologic underpinnings that determine risk for obesity and related complications.
Advertisement
Advertisement
Related to this article
New American Society of Hematology guidelines raise ferritin cutoffs to catch iron deficiency sooner, including pregnancy and inflammation, and add TSAT for clearer diagnosis.
The US FDA cleared a novel insulin patch pump that can be used for up to 3 days with an additional 12-hour grace period in persons with diabetes.
Takeda’s oral TYK2 inhibitor showed rapid skin clearance in phase 3 psoriasis trials as FDA fast-tracks review; decision expected early 2027.
The FDA accepted Organon’s MIUDELLA supplemental application, but the proposed change, supporting data, and review timeline remain undisclosed.
Axsome has launched the SUMMIT phase 3 clinical trial evaluating AXS-05 to help adults quit smoking, comparing it with bupropion and placebo over 12 weeks.
A new scientific statement calls for a shift in obesity management and treatment to focus on overall health improvements rather than just weight loss alone.
New research underscores the need for public health interventions to improve the microbial and fiber content of diets in the US.
Advertisement
Advertisement
Trending on Patient Care Online
1
ASH Raises Ferritin Thresholds for Diagnosing Iron Deficiency
2
Elevated PSA in Primary Care: What to Consider Before Biopsy
3
Combating Prostate Cancer Misconceptions in Primary Care: An Expert Discussion
4
FDA Grants Priority Review to Zasocitinib for Plaque Psoriasis
5